SCHEMBL7737595

SCHEMBL7737595

CSc1cccc(NC(=O)c2ccccc2)c1NCc1ccncc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.63
KMT2A Q03164 2/20 0.63
NPSR1 Q6W5P4 1/20 0.63
HSD17B10 Q99714 1/20 0.63
ALDH1A1 P00352 2/20 0.53
ALOX15 P16050 1/20 0.53
HTT P42858 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HDAC1 Q13547 4/20 0.51
NAMPT P43490 6/20 0.47
CCR8 P51685 1/20 0.47
MAPT P10636 1/20 0.46
MDM4 O15151 1/20 0.45
MDM2 Q00987 1/20 0.45
POLB P06746 1/20 0.45
KDM4E B2RXH2 1/20 0.44
HDAC3 O15379 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4976161 0.79 NPSR1 (0.61) TP53KMT2ANPSR1HSD17B10ALDH1A1
SCHEMBL28189189 0.75 KMT2A (0.76) TP53KMT2ANPSR1HSD17B10ALDH1A1
SCHEMBL7295905 0.71 KMT2A (0.60) TP53KMT2ANPSR1HSD17B10ALDH1A1
SCHEMBL2339343 0.70 ALDH1A1 (1.00) TP53KMT2ANPSR1HSD17B10ALDH1A1
SCHEMBL6445765 0.69 TDP1 (0.59) TP53KMT2ANPSR1HSD17B10ALDH1A1
SCHEMBL13212285 0.69 TP53 (0.79) TP53KMT2ANPSR1HSD17B10ALDH1A1
SCHEMBL30434731 0.69 CCR8 (0.67) ALDH1A1HTTNAMPTCCR8KDM4E
SCHEMBL7854832 0.69 NPC1 (0.56) TP53KMT2ANPSR1ALDH1A1L3MBTL1
SCHEMBL1161697 0.68 MMP13 (0.82) ALDH1A1HTTL3MBTL1HDAC1NAMPT
SCHEMBL28277563 0.68 KMT2A (0.64) TP53KMT2ANPSR1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, KDR TP53 1416/4885KMT2A 2604/4885NPSR1 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.